Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 38

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
596)  (4,433)  (112)  (9,141)                  (LOSS)/PROFIT BEFORE TAX   (109,700)  804,393   (523,694)  170,999                   Tax expense   -   (75,652)  -   (75,652)                  NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS   $(109,700) $728,741  $(523,694) $95,347 

 28Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   As of June 30, 2025              Segment assets  $2,502,665  $6,320,015  $598,525  $9,421,205                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  -   30,511   -   30,511     Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   As of December 31, 2024              Segment assets  $2,652,754  $6,788,302  $992,792  $10,433,848                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  150,881   221,844   -   372,725  The Company had no inter-segment sales for the periods presented. 

 29Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency